The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Histone Lysine Acetyltransferase Inhibitor

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven.

Please acknowledge that you understand this before proceeding.

Back

Molecule overview Clinical trials

Histone Lysine Acetyltransferase Inhibitor

PF-08032562 | KAT6/7 is an investigational compound. Its safety and efficacy have not been established.

Overview + Rationale Mechanism of Action Stage of Development

Share to an HCP

Overview + Rationale

PF-08032562 is an investigational small‑molecule inhibitor targeting the lysine acetyltransferases KAT6A/B and KAT7
KAT6A/B and KAT7 complexes are involved in histone lysine acetylation, which is associated with chromatin regulation and gene expression
In pre‑clinical models, PF-08032562 has been studied for its impact on transcriptional programs, including cell cycle, MYC, ER, and lineage‑associated pathways in solid tumors

Mechanism of Action

Stage of Development

Advanced Solid Tumors

Phase 1 Monotherapy and Combination

Histone Lysine Acetyltransferase Inhibitor

Geo Regions

Histone Lysine Acetyltransferase Inhibitor

Overview + Rationale

Mechanism of Action

Stage of Development

Advanced Solid Tumors

This information is current as of February 27th 2026.